CLINICAL_TRIALS
trial_result
· 2011-09-13
Clinical Trial Update: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines [Phase 3]
Summary
Phase 3 trial comparing Xeomin (incobotulinumtoxinA) to placebo for moderate to severe glabellar frown lines has completed. Results were posted in 2011.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merz Pharmaceuticals GmbH | Conditions: Moderate to Severe Glabellar Frown Lines | Phase 3 | Status: COMPLETED | Results posted: 2011-09-13